Can PSA velocity serve as a surrogate endpoint in trials of hormone-refractory, metastatic prostate cancer?: Commentary

John F. Ward

doi:10.1038/ncpuro0504

Can PSA velocity serve as a surrogate endpoint in trials of hormone-refractory, metastatic prostate cancer? Commentary

Research output: Contribution to journal › Short survey › peer-review

Original language	English (US)
Pages (from-to)	310-311
Number of pages	2
Journal	Nature Clinical Practice Urology
Volume	3
Issue number	6
DOIs	https://doi.org/10.1038/ncpuro0504
State	Published - Jun 2006
Externally published	Yes

Keywords

Cytostatic therapy
Hormone refractory
PSA velocity
Prostate cancer
Survival

ASJC Scopus subject areas

Urology

Access to Document

10.1038/ncpuro0504

Cite this

@article{d590066b800541fd96f1814bf595639a,

title = "Can PSA velocity serve as a surrogate endpoint in trials of hormone-refractory, metastatic prostate cancer?: Commentary",

keywords = "Cytostatic therapy, Hormone refractory, PSA velocity, Prostate cancer, Survival",

author = "Ward, {John F.}",

year = "2006",

month = jun,

doi = "10.1038/ncpuro0504",

language = "English (US)",

volume = "3",

pages = "310--311",

journal = "Nature Clinical Practice Urology",

issn = "1743-4270",

publisher = "Nature Publishing Group",

number = "6",

}

TY - JOUR

T1 - Can PSA velocity serve as a surrogate endpoint in trials of hormone-refractory, metastatic prostate cancer?

T2 - Commentary

AU - Ward, John F.

PY - 2006/6

Y1 - 2006/6

KW - Cytostatic therapy

KW - Hormone refractory

KW - PSA velocity

KW - Prostate cancer

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=33745021850&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745021850&partnerID=8YFLogxK

U2 - 10.1038/ncpuro0504

DO - 10.1038/ncpuro0504

M3 - Short survey

C2 - 16763642

AN - SCOPUS:33745021850

SN - 1743-4270

VL - 3

SP - 310

EP - 311

JO - Nature Clinical Practice Urology

JF - Nature Clinical Practice Urology

IS - 6

ER -

Can PSA velocity serve as a surrogate endpoint in trials of hormone-refractory, metastatic prostate cancer? Commentary

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this